Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

LONDON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 2:30 p.m. Greenwich Mean Time (9:30 a.m.

GlobeNewsWire • Nov 12, 2025

Kiniksa: How Category Ownership And Higher Duration Are Translating Into Operating Leverage

Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180.9M (+61% YoY, +15% QoQ), prompting raised FY2025 guidance to $670–$675M. ARCALYST's efficacy and new ACC guidance support increased patient-months, leading to a more steady revenue stream and reposition users for longer-term use.

Seeking Alpha • Oct 30, 2025

New Strong Sell Stocks for Oct. 30th

EQX, GDEN and KNSA have been added to the Zacks Rank #5 (Strong Sell) List on October 30, 2025.

Zacks Investment Research • Oct 30, 2025

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jonathan Kirshenbaum - Investor Relations Officer Sanj Patel - CEO & Chairman of the Board Ross Moat - Executive VP & Chief Commercial Officer Mark Ragosa - Senior VP & CFO John Paolini - Executive VP & Chief Medical Officer Conference Call Participants Mary Kate Davis Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Nicholas Lorusso - TD Cowen, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division David Nierengarten - Wedbush Securities Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Oct 28, 2025

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today –

GlobeNewsWire • Oct 28, 2025

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings Miss Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to a loss of $0.18 per share a year ago.

Zacks Investment Research • Oct 28, 2025

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution.

GlobeNewsWire • Oct 23, 2025

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling activity of the cytokines interleukin-1α (IL-1α) and interleukin-1β (IL-1β).

GlobeNewsWire • Oct 17, 2025

Why Kiniksa Pharmaceuticals International, plc (KNSA) is Poised to Beat Earnings Estimates Again

Kiniksa Pharmaceuticals International, plc (KNSA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 16, 2025

Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet

The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Oct 14, 2025